Covid-19 in Patients With Cancer Publisher Pubmed



Nowroozi A^{1, 2} ; Razi S^{1, 3} ; Sahu KK^{4, 5} ; Grizzi F^{6, 7} ; Arends J^{8, 9} ; Keshavarzfathi M^{1, 2} ; Rezaei N^{10, 11, 12}
Source: Advances in Experimental Medicine and Biology Published:2021

Abstract

With more than 5 million cases and 333,212 deaths, COVID-19 (or SARS-CoV-2) continues to spread. General symptoms of this disease are similar to that of many other viral respiratory diseases, including fever, cough, dyspnea, and fatigue, with a chance of progression to more severe complications. However, the virus does not affect all people equally, and cases with comorbidities such as malignancies, cardiovascular diseases, respiratory diseases, and kidney diseases are at higher risk of developing severe events, including requiring intensive ventilation, intensive care unit (ICU) admission, and death. Patients with cancer are more likely to be infected with COVID-19, which is possibly due to their immunological dysfunction or frequent clinic visits. Also, there is a higher chance that these patients experience severe events because of the medication they receive. In this chapter, we will review the main clinical manifestations of COVID-19 in patients with cancer. Recommendations and challenges for managing resources, organizing cancer centers, treatment of COVID-19-infected cancer patients, and performing cancer research during this pandemic will also be discussed. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.